Cyclophosphamide /Kg

Small molecule

AAlice Bertaina

Cyclophosphamide /Kg is one of 26 small molecule programs targeting Kidney Transplant. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Kidney TransplantPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Medrol

Pfizer

Preclinical

12 3

Zinbryta

Roche

Preclinical

6 4

Sensipar

Amgen

Preclinical

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 8

Jardiance

Boehringer Ingelheim

Preclinical

3 9

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2034

Phase 1/2Recruiting

Kidney Transplant

NCT05508009

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Recruiting·AAlice Bertaina·Phase 1/2·NCT05508009·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cyclophosphamide /Kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclophosphamide /Kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclophosphamide /Kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alice Bertaina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAlice Bertaina

Cyclophosphamide /Kg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2034

Trials by Indication[1]

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News